NOVARTIS AG-REG (1NOVN.MI) Stock Price & Overview

BIT:1NOVN • CH0012005267

Current stock price

135 EUR
+1 (+0.75%)
Last:

The current stock price of 1NOVN.MI is 135 EUR. Today 1NOVN.MI is up by 0.75%. In the past month the price increased by 18.42%.

1NOVN.MI Key Statistics

1-Month Range111 - 148
Current 1NOVN.MI stock price positioned within its 1-month range.
Market Cap
259.037B
P/E
17.35
Fwd P/E
17.24
EPS (TTM)
7.78
Dividend Yield
2.96%

1NOVN.MI Stock Performance

Today
+0.75%
1 Week
-8.16%
1 Month
+18.42%
3 Months
+15.38%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1NOVN.MI Stock Chart

NOVARTIS AG-REG / 1NOVN Daily stock chart

1NOVN.MI Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 1NOVN.MI.


Chartmill TA Rating
Chartmill Setup Rating

1NOVN.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1NOVN.MI. 1NOVN.MI gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1NOVN.MI Earnings

On February 4, 2026 1NOVN.MI reported an EPS of 2.03 and a revenue of 13.34B. The company missed EPS expectations (-0.17% surprise) and missed revenue expectations (-4.89% surprise).

Next Earnings DateApr 27, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$2.03
Revenue Reported13.336B
EPS Surprise -0.17%
Revenue Surprise -4.89%

1NOVN.MI Forecast & Estimates

34 analysts have analysed 1NOVN.MI and the average price target is 132.6 EUR. This implies a price decrease of -1.78% is expected in the next year compared to the current price of 135.

For the next year, analysts expect an EPS growth of 0.69% and a revenue growth 2.75% for 1NOVN.MI


Analysts
Analysts70.59
Price Target132.6 (-1.78%)
EPS Next Y0.69%
Revenue Next Year2.75%

1NOVN.MI Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

1NOVN.MI Financial Highlights

Over the last trailing twelve months 1NOVN.MI reported a non-GAAP Earnings per Share(EPS) of 7.78. The EPS increased by 14.98% compared to the year before.


Income Statements
Revenue(TTM)56.33B
Net Income(TTM)13.98B
Industry RankSector Rank
PM (TTM) 24.83%
ROA 12.6%
ROE 30.31%
Debt/Equity 0.64
Chartmill High Growth Momentum
EPS Q2Q%2.53%
Sales Q2Q%1.39%
EPS 1Y (TTM)14.98%
Revenue 1Y (TTM)8.91%

1NOVN.MI Ownership

Ownership
Inst Owners41.7%
Shares1.92B
Float1.70B
Ins Owners0.03%
Short Float %N/A
Short RatioN/A

1NOVN.MI Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
SNW SANOFI9.01184.842B
SAN SANOFI9.01184.817B
1SAN SANOFI9.01184.6B
UNC UCB SA24.2749.211B
UCB UCB SA24.2749.133B
1MRK MERCK KGAA12.948.217B
MRK MERCK KGAA13.0447.587B
BAYN BAYER AG-REG8.2538.442B
1BAYN BAYER AG-REG8.3638.422B
IPN IPSEN12.4812.848B
REC RECORDATI INDUSTRIA CHIMICA15.879.733B
TUB FINANCIERE DE TUBIZE N/A9.681B
VIRP VIRBAC SA15.372.806B

About 1NOVN.MI

Company Profile

1NOVN logo image Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

IPO: 2001-05-07

NOVARTIS AG-REG

Lichtstrasse 35

Basel BASEL-STADT CH

Employees: 75883

1NOVN Company Website

1NOVN Investor Relations

Phone: 41613241111

NOVARTIS AG-REG / 1NOVN.MI FAQ

What does NOVARTIS AG-REG do?

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.


What is the current price of 1NOVN stock?

The current stock price of 1NOVN.MI is 135 EUR. The price increased by 0.75% in the last trading session.


What is the dividend status of NOVARTIS AG-REG?

NOVARTIS AG-REG (1NOVN.MI) has a dividend yield of 2.96%. The yearly dividend amount is currently 3.47.


How is the ChartMill rating for NOVARTIS AG-REG?

1NOVN.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is NOVARTIS AG-REG (1NOVN.MI) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1NOVN.MI.


How many employees does NOVARTIS AG-REG have?

NOVARTIS AG-REG (1NOVN.MI) currently has 75883 employees.


Can you provide the market cap for NOVARTIS AG-REG?

NOVARTIS AG-REG (1NOVN.MI) has a market capitalization of 259.04B EUR. This makes 1NOVN.MI a Mega Cap stock.